ライフサイエンスコーパス: statistical analysis plan

1 itional, protocol-prespecified secondary endpoint data, and statistical analysis plan-prespecified descriptive endpoints

2 using the data sets, data dictionary, case report file, and statistical analysis plan from the original trial accessed th

3 he context of negative findings for the primary outcome and statistical analysis plan, this lower incidence was not consi

4 s (405 studies [86.5%] vs 87 studies [65.9%]; P < .001) and statistical analysis plans (373 studies [79.7%] vs 73 studies

5 ing framework for study designs, sample size estimates, and statistical analysis plans for future pivotal trials of islet

6 that they planned to share data and make both protocols and statistical analysis plans available, raw data and code were

7 To ensure transparency, protocols and statistical analysis plans need to be published, and investig

8 Trial registration, protocols, and statistical analysis plans are critically important in ensuri

9 tion drives experimental design, randomization schemes, and statistical analysis plans, while neglecting social context.

10 A detailed statistical analysis plan was written and finalized on July 7

11 Following a prospectively developed statistical analysis plan, we reanalyzed safety data from eig

12 The HRQOL statistical analysis plan prespecified eight aspects of HRQOL

13 is an absence of guidance covering the required content of statistical analysis plans (SAPs) to support transparency and

14 This paper reports guidelines for the content of statistical analysis plans for early phase clinical trials, e

15 ethodology are that we did not have an a priori protocol or statistical analysis plan because the analysis was initially

16 arters of trials had full protocols (482 trials [82.0%]) or statistical analysis plans (446 trials [74.3%]) available, bu

17 red between January 27 and September 4, 2023, following our statistical analysis plan.

18 Clinical trials need a predefined statistical analysis plan for uses of baseline data, especial

19 ratified design accounted for by following the prepublished statistical analysis plan.

20 Blinded intention-to-treat analysis based on a prespecified statistical analysis plan included all participants eligible

21 Analyses were conducted according to a prespecified statistical analysis plan, using multiple logistic regression

22 h trial, we compared internal company documents (protocols, statistical analysis plans, and research reports, all unpubli

23 types of efficacy analyses were described in the protocols, statistical analysis plans, and publications, including ITT a

24 (sponsor, author, and analyst) and transparency (protocols, statistical analysis plans, and data and code availability).

25 analyzed as intention-to-treat according to a pre-specified statistical analysis plan.

26 The statistical analysis plan prespecified comparisons of cogniti

27 The statistical analysis plan specified that if the between-group

28 The statistical analysis plan was pre-specified in a protocol.

29 The statistical analysis plan was prespecified with a primary hyp

30 ped after an unplanned interim analysis of cohort 1 and the statistical analysis plan for the primary endpoint was amende

31 All analyses were prespecified in the protocol and the statistical analysis plan.

32 eduction in VAT were defined a priori as responders per the statistical analysis plan.

33 Four studies (13%) published the statistical analysis plan and prespecified use of RWD.

34 y and will be reported when the timepoint, according to the statistical analysis plan, has been reached.

35 l trials should include a stacked probability plot in their statistical analysis plan as descriptive analysis.